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Abstract
Introduction: Staphylococcus aureus is a major cause of health care 
associated infections worldwide.
Objective: The aim of this work was to evaluate epidemiological 
characteristics and antimicrobial susceptibility of Methicillin-resistant 
S. aureus (MRSA) strains isolates from infections in a Brazilian tertiary 
hospital.
Methods: Clinical and epidemiological data of the patients were 
collected. Bacterial strains were isolated and identified using the clas-
sical identification tests. Antimicrobial susceptibility assays were per-
formed using the disc-diffusion method.
Findings: A total of 590 samples of S. aureus were isolated from 
patients and 42.5% were characterized as MRSA. Considering the 
clinical specimens, most of samples were isolated from blood and 
tracheal secretion, catheter tip, surgical site swabs, wound secre-
tion, exudates and urine. Overall, a high frequency of resistance was 
observed against ciprofloxacin, clindamycin, erythromycin, amikacin, 
gentamicin, trimethoprim-sulfamethoxazole, tetracycline and chlo-
ramphenicol. Association between death and multidrug-resistance 
in elderly patients, and death and occurrence of bacteremia by mul-
tidrug-resistant MRSA was observed.
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Introduction
The Gram positive cocci Staphylococcus aureus is 
one of the most common microorganisms isolated 
from infections related to health care around the 
world. This scenario has gotten worse over time 
due to an increase in antimicrobial resistance rate, 
especially to methicillin, a penicillinase-resistant se-
misynthetic penicillin, antimicrobial of choice for the 
treatment of infections caused by antimicrobial-re-
sistant S. aureus [1-3].
Methicillin-resistant S. aureus (MRSA) are resis-
tant to other penicillins other β-lactams such as 
cephalosporins, carbapenems and monobactams 
[4]. These bacteria, initially related to infections as-
sociated to health care (hospital-acquired methi-
cillin-resistant Staphylococcus aureus HA-MRSA), 
nowadays also represent a major problem in the 
community (community-associated methicillin-
resistant Staphylococcus aureus CA-MRSA) [5,6]. 
While the community-associated MRSA diseases 
are related to skin infections, the more severe cli-
nical infections are more frequently related to hos-
pitalized patients [7].
Although in Brazil, researches show a high fre-
quency of MRSA colonization in patients with bac-
teremia, [8,9] the most of the scientific data consi-
dering epidemiology and antimicrobial susceptibility 
patterns of MRSA to other antimicrobial, are origi-
nated in other countries. Thus, the available infor-
mation is not, indeed, representative of the Brazilian 
reality, which makes difficult to guide the empiri-
cal chemotherapy. In this respect, considering the 
worldwide spread of MRSA and the lack of regional 
data on HA-MRSA epidemiology and antimicrobial 
susceptibility patterns, the aim of this study was to 
describe epidemiological characteristics and antimi-
crobial susceptibility trends of MRSA strains asso-
ciated to patients admitted to a tertiary hospital, 
between 2005 and 2010, in Brazil.
Methods
The study was conducted at a teaching hospital in 
Juiz de Fora, MG, Brazil. It is a tertiary institution 
with 146 beds, and six of them are in an Intensive 
Care Unit (ICU). A total of 590 samples of S. aureus 
were isolated and identified from different clinical 
specimens from patients admitted between 2005 
and 42.5% (n=251) were characterized as MRSA. 
Considering only the non-replicate isolates, 103 
MRSA strains were considered in this study (Table 
1), which was approved by the Ethics Committee 
of the Federal University of Juiz de Fora (certificate 
no. 267/2011). Clinical and epidemiological data of 
the patients were collected from medical records 
and record books from the clinical microbiology la-
boratory Prof. Maurilio Baldi at the UFJF Teaching 
Hospital. 
All the clinical specimens were inoculated in Man-
nitol Salt Agar (Difco, USA) with a 0.001 mL sterile 
loop and incubated at 35.5ºC for up to 48 hours. 
Bacterial strains (3 to 5 colonies/clinical specimens) 
in monomicrobial cultures were isolated and iden-
tified using the classical identification tests [10]. 
Antimicrobial susceptibility assays were performed 
on Mueller–Hinton agar (HiMedia) using the disc-
diffusion method and growth inhibition zones were 
interpreted according to the Clinical and Laboratory 
Conclusions: Our data are highly relevant for surveillance systems 
and to map on a wider scale the dynamics of circulation of MRSA 
and raise discussions on containment strategies and rational use of 
empiric chemotherapy.
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Table 1.  Epidemiological parameters and frequency of antimicrobial resistance in MRSA strains associated 
to patients admitted to a tertiary hospital over a 6-year period.
Epidemiological parameters
Sampled period
2005 2006 2007 2008 2009 2010
(n=25) (n=13) (n=27) (n=21) (n=10) (n=07)
Gender
Male 72.0% 69.2% 74% 66.6% 70.0% 71.4%
Female 28.0% 30.8% 26% 33.4% 30.0% 28.6%
Average age (years) 50.2 54.9 52.2 56.5 58.5 64.4
Type of Infection
Bacteremia 4.0% 23.1% 22.2% 33.3% 30.0% 14.3%
Catheter bacteremia 12.0% 30.7% 11.1% 14.3% 10.0% 0.0%
Surgical Site 28.0% 0.0% 18.5 14.3% 0.0% 0.0%
Wound infection 0.0% 0.0% 11.1% 4.8% 10.0% 14.3%
Digestive system 8.0% 0.0% 7.4% 0.0% 0.0% 0.0%
Musculoskeletal 8.0% 0.0% 3.8% 0.0% 0.0% 0.0%
Respiratory system 36.0% 46.2% 18.5% 23.8% 50.0% 71.4%
UTI 4.0% 0.0% 7.4% 9.5% 0.0% 0.0%
Clinical specimens
Blood 20.0% 15.4% 18.5% 38.1% 30.0% 14.3%
Tracheal secretion 20.0% 30.8% 18.5% 14.3% 50.0% 71.4%
Urine 4.0% 0.0% 7.5% 9.5% 0.0% 0.0%
Catheter tip 16.0% 30.8% 11.1% 19.0% 10.0% 0.0%
Exudates 12.0% 23.0% 22.2% 4.8% 10.0% 14.3%
Surgical Site Swabs 28.0% 0.0% 22.2% 14.3% 0.0% 0.0%
Patient evolution
Discharged 56.0% 46.1% 55.5% 61.9% 30.0% 57.1%
Death 36.0% 53.9% 44.5% 38.1% 60.0% 42.9%
Transference 8.0% 0.0% 0.0% 0.0% 10.0% 0.0%
Hospital section
Infirmary 24.0% 23.1% 22.2% 42.9% 40.0% 14.3%
Surgery 36.0% 23.1% 29.6% 14.3% 0.0% 14.3%
Intensive care 36.0% 53.8% 44.4% 33.3% 50.0% 71.4%
Pediatric 4.0% 0.0% 0.0% 9.5% 10.0% 0.0%
BMT 0.0% 0.0% 3.8% 0.0% 0.0% 0.0%
UTI (urinary tract infection); BMT (Bone marrow transplantation).
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Standards Institute (CLSI) [11]. Antimicrobial discs 
amikacin (30µg), ciprofloxacin (5µg),clindamycin 
(2µg), chloramphenicol (30µg), erythromycin (15µg), 
gentamicin (10µg), trimethoprim-sulfamethoxazole 
(25µg), tetracycline (30µg) and were of commercial 
grade (Laborclin Ltda, Brazil). To evaluated the resis-
tant to vancomycin E-test® was used (AB Biodisk, 
Solna, Sweden). MRSA was detected by resistance 
to cefoxitin (30µg) and oxacillin (1µg) disks. Staphylo-
coccus aureus ATCC 25923 was used for quality 
control. Besides the descriptive analysis, univariate 
analysis were performed estimating the odds ratios 
(OR) with their respective 95% confidence intervals 
(CI) to verify the associations between microbial re-
sistance with discharged, transferred and deceased 
patients. The same analysis were performed among 
the type of MRSA infection and patient’s age and 
outcome (p<0.05). For means comparisons the 
Mann-Whitney test was used. The comparison of 
each factor was done by the non parametric Fisher’s 
exact test.
Results 
Detailed clinical and epidemiological characteristics 
of the patients are presented in table 1. Overall, 
71% of bacteria were recovered from male patients 
and 29% from female. The average age was 54.4 
years old. Overall, positive correlations between age 
or gender, and MRSA infected patients were not 
observed (p = 1.00). Although mainly associated 
to patients admitted in intensive care unit (43.7%), 
MRSA were also isolate from patients admitted to 
adult infirmary (28.1%), surgical unit (23.3%), pedia-
trics (3.9%) and bone marrow transplantation unit 
(1%). Considering the associated infections, 34% 
and 20.4% of the samples were isolated from respi-
ratory tract and bacteremia infections, respectively. 
MRSA was also isolated from surgical site, catheter-
related bacteremia, wound infections, infections of 
the musculoskeletal system, tract urinary and diges-
tive system. 
Considering the clinical specimens, most of sam-
ples were isolated from tracheal secretion and 
blood (26.2% and 23.3% respectively) followed by 
surgical site swabs, catheter tip, exudates, wound 
secretion and urine (Table 1). Regarding to the pa-
tients, 53.4% were discharged, 43.6% died and 3% 
were transferred to other hospitals. 
Overall, a high frequency of resistance was ob-
served against ciprofloxacin (92.5%), clindamycin 
(89.7%), erythromycin (86.9%), amikacin (73.8%), 
gentamicin (70%), trimethoprim-sulfamethoxazole 
(63.5%), tetracycline (60.7 %) and chlorampheni-
col (52.3%). No bacterial resistance was observed 
against vancomycin (Figure 1). 
Association between death and multirresistant 
MRSA was observed in elderly patients (OR=3.57-
95% CI: 0.3-38.8). Association was also observed 
between death and the occurrence of bacteremia in 
patients with multirresistant MRSA (OR=1.57-95% 
CI: 0.2-10.4). However these associations were not 
considered significant.
When considering MRSA occurrence over time 
and their antimicrobial susceptibility, alterations in 
the resistance patterns were observed. In 2005, 
from the tested drugs, the most effective antimi-
crobial was chloramphenicol, and high resistance 
levels were observed against amikacin, ciprofloxa-
cin, clindamycin, erythromycin, gentamicin, tri-
methoprim-sulfamethoxazole and tetracycline. In 
2006, increased resistance was observed against 
all tested drugs with rates of 100% resistance 
against ciprofloxacin, clindamycin, gentamicin, and 
trimethoprim-sulfamethoxazole. In the subsequent 
two years, decreased resistance was observed, es-
pecially in 2008, with exception for chlorampheni-
col in 2007. In 2009 it was observed high levels of 
sensitivity to amikacin, gentamicin, trimethoprim-
sulfamethoxazole and tetracycline (90%). In 2010, 
there was a re-emergence of high resistance levels 
(100%), especially against ciprofloxacin, clindamy-
cin and erythromycin. Considering amikacin, gen-
tamicin, trimethoprim-sulfamethoxazole and tetra-
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cycline, although it has been observed an increa-
sed resistance compared to the previous year, the 
resistance rates remained relatively low (28.6%). 
Discussion
Methicillin-resistant Staphylococcus aureus has be-
come a global problem and active surveillance for 
this pathogen, with appropriate prevention mea-
sures, can reduce its infections rates and reduce 
treatment costs [12]. This study showed the clini-
cal epidemiology of MRSA isolates from inpatients, 
identifying the distribution of this pathogen in di-
fferent sections, associated with gender and ave-
rage and more age type of infection, clinical speci-
mens, and patient evolution of a teaching hospital. 
The results obtained demonstrate there was no 
statistically significant difference when the mean 
age of patients was compared among the years 
of the study (p>0.05). The incidence of MRSA in-
fections is among the highest in the elderly popu-
lation [13]. Study conducted in Sacramento, EUA, 
demonstrated that the average age of health care 
associated-MRSA patients was 54, which was 15 
years older than the average age of patients with 
community associated-MRSA [14].
It is accepted that morbidity and mortality rates 
especially from infections with MRSA in bloods-
tream tend to be even greater in the elderly due 
to their physiological conditions and immunologi-
cal status [15]. The impact of methicillin-resistance 
on mortality among patients infected with S. au-
reus has been primarily evaluated in patients with 
bacteremia, and the results were variable [8,16]. A 
meta-analysis involving studies with mortality data 
published between the years 1980 to 2000 was 
performed. Among 31 cohort studies including 
3.963 patients, of whom 34% were infected with 
Figure 1:  Antimicrobial susceptibility of Methicillin-resistant Staphylococcus aureus (MRSA) in a tertiary hospi-
tal over a 6-year period. AK, amikacin; CP, ciprofloxacin; CD, clindamycin; CL, chloramphenicol; EM, 
erytromycin; GM, gentamicin, TS, trimethoprim-sulfamethoxazole; TE, tetracycline; VA, vancomycin.
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MRSA, there was a significant increase in mortality 
associated with bacteremia [17]. Although there are 
few national data to compare our results, according 
to the literature methicillin-resistance significantly 
increased in the early 2000s in developed regions, 
such as the European countries [18] and the USA 
[19] and developing regions such as Latin America 
[20].
In Brazil, oxacillin is used as penicillinase-resistant 
semisynthetic penicillin, being oxacillin-resistant S. 
aureus (ORSA) equivalent to the MRSA strains in 
other regions. Reports from different hospitals bet-
ween 1997 and 2001 with totalizing 1.516 S. au-
reus samples showed resistance rates of oxacillin 
resistance as of 3.8% [21]. Reports comprising the 
period between 2005 and 2008, involving 2.218 
samples, showed ORSA occurrence of 31.0%, and 
most of these bacteria were also resistant against 
erythromycin, clindamycin, ciprofloxacin, and levo-
floxacin [22]. With regard to the ORSA observations, 
our data corroborate these previous studies. An in-
crease in MRSA-associated hospital infections has 
been reported in intensive care units in USA, which 
ranged from only 2% in 1974 to rates of 22% in 
1995 and 64% in 2004 [23]. Subsequent studies 
showed stabilization in this tendency with rates of 
56% between 2006 and 2007 [24].
Another study conducted in a teaching hospital 
in the USA, which evaluated MRSA colonization or 
infections in hospitalized patients revealed that the 
most common types of infections were bactere-
mia (28%), pneumonia (20%), soft tissue infections 
(16%), and bones or joints infections (16%) [25]. 
Overall, the most frequently reported risk factors re-
lated to the acquisition of MRSA bacteremia include 
previous antibiotic chemotherapy, prolonged stay in 
ICU, previous MRSA infection and colonization, use 
of invasive devices such as central venous catheters 
and urinary catheter, previous hospitalization and 
presence of co-morbidities [9, 26].
The therapy used for MRSA infections is still rather 
limited. Some drugs have been used in recent years 
such as dalfopristin, linezolid, tigecycline and dap-
tomycin [27, 28]. However, the use of vancomycin 
is still the choice for treatment of these infections. 
The increase use of glycopeptides has facilitated the 
selection of resistance and the high toxicity caused 
in the human body, have shown the necessity of 
the restricted use of these antimicrobials [29, 30].
As a whole, the dynamics of antimicrobial resistan-
ce, observed in this study, show that the widespread 
use of ciprofloxacin, clindamycin and erythromycin 
should not be encouraged as the first empiric the-
rapy option. By the other hand, the effectiveness 
of drugs such as chloramphenicol might be related 
to its low prescription over the years in our region. 
Based on results from antimicrobial susceptibility 
testing, the use of amikacin, gentamicin, tetracy-
cline and trimethoprim-sulfamethoxazole should be 
sustained due to the variations observed for their 
effectiveness among the isolated bacteria. 
We observed vancomycin as the most effective 
drug; other authors also suggest that it should be 
used only for serious infections, when other antimi-
crobials are without therapeutic effect [29,30]. His-
torically, the occurrence of antimicrobial resistance 
is inevitable. This is due to the natural species evo-
lution caused by environmental selective pressures. 
In this respect, retrospective studies on antimicrobial 
susceptibility patterns should improve strategies to 
limit the emergence of multi-drug-resistant bacterial 
strains. 
Our data are highly relevant not only for survei-
llance systems, but to map on a wider scale the 
dynamics of circulation of such microorganism and 
raise discussions on containment strategies and ra-
tional use of empiric chemotherapy.
Conclusion
This study showed relevant data on the levels of 
MRSA in critical areas and associated specimens 
respiratory tract secretions and blood. The high le-
vels of antimicrobial resistance suggest the extent of 
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the phenomenon and confirm data from the recent 
literature on the nature of the multidrug-resistant 
strains of S. aureus. Retrospective studies on an-
timicrobial susceptibility patterns should improve 
strategies to limit the emergence of multi-drug-
resistant bacteria. Our data are highly relevant for 
surveillance systems and to map on a wider scale 
the dynamics of circulation of MRSA and raise dis-
cussions on containment strategies and rational use 
of empiric chemotherapy
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